Southern Illinois University School of Medicine

EQS-News: International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools

Retrieved on: 
Wednesday, September 6, 2023
Royal Surrey County Hospital, Hospice and palliative medicine, University, Consultant, E pluribus unum, RRT, Critical Care (journal), Overalls, Renal replacement therapy, Biomarker, AKI, Intensive care medicine, Acute kidney injury, CRRT, Professor, University Hospital Heidelberg, Patient, School, RICH, Mortality, University of Surrey, Intensive care unit, Health, Southern Illinois University School of Medicine, Pharmaceutical industry, Medical imaging, Nursing

Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.

Key Points: 
  • Recently published scientific data affirms that penKid remains informative under acute renal replacement therapy (RRT) and can identify patients for successful liberation.
  • RRT, a common practice in Intensive Care Units (ICUs), has long relied on clinical observations for stop decisions.
  • However, the lack of a dependable biomarker poses challenges in accurately assessing when to discontinue RRT.
  • Considering this, leading experts from the field have discussed in a recent advisory board the importance of identifying the right tools to improve the outcomes in AKI.

Advancing Medicine Requires a Sex and Gender Lens

Retrieved on: 
Wednesday, December 7, 2022
American Medical Women's Association, NIH, Physician, Prognosis, Southern Illinois University School of Medicine, Speech, Health education, Diagnosis, Biomedical Research, Patient, Communication, Mayo Clinic, AMWA, Public, Research, Disease, Medicine, Woman, Women's health, Geography, Multimedia, Clinical research, Education, University School, Health, Pharmacokinetics, Student, Risk management, Toy

SCHAUMBURG, Ill., Dec. 7, 2022 /PRNewswire/ -- Addressing the need for sex and gender considerations from research to patient management remained the focus of the fourth Sex and Gender Health Education (SGHE) Summit, held virtually in November 2021, and organized by American Medical Women's Association, Mayo Clinic, Laura Bush Institute for Women's Health, and Southern Illinois University School of Medicine, with support from other national organizations. Proceedings of this important series-culminating program have been published today.

Key Points: 
  • "We need a broader vision for women's health; one that necessitates that sex and/or gender are integrated into biomedical research."
  • Adopt a multi-professional lens to introduce teaching strategies centered on sex and gender differences in pathophysiology, clinical care, and pharmacokinetics.
  • Expose systemic biases in health education by integrating sex and gender considerations into understanding of symptomatology, response to disease management and treatment, all of which impact outcomes.
  • American Medical Women's Association is a multispecialty organization of women physicians committed to advancing women in medicine, advocating for equity, and ensuring excellence in health care.

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

Retrieved on: 
Tuesday, November 15, 2022
Linda, SEC, Compte rendu, M.B.A, Haemophilia, U.S. Securities and Exchange Commission, Security (finance), MAA, Investigational New Drug, European Medicines Agency, Enzyme, Southern Illinois University School of Medicine, Therapy, Biology, Forward-looking statement, Risk, NDA, Leadership, Homocystinuria, New Drug Application, Medicine, Industry, Adverum Biotechnologies, Multimedia, Patient, Indiana Wesleyan University, COVID-19, NASDAQ, Ophthalmology, University School, Private Securities Litigation Reform Act, Review, IND, Drug development, Engineering, Arginine, Pharmaceutical industry, Management, Catalysis, Southern Illinois University

AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer.

Key Points: 
  • AUSTIN, Texas, Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer.
  • D., J.D., interim chief executive officer and general counsel of Aeglea.
  • I am excited to continue working closely with Linda as a valued member of our executive leadership team."
  • Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options.

Meridian Awards $500,000 Grant to SIU Medicine Office of Diversity, Equity, and Inclusion

Retrieved on: 
Thursday, August 11, 2022
Multimedia, Southern Illinois University School of Medicine, Faculty, Ecosystem, School, Research, Workforce, Hospital Insurance and Diagnostic Services Act, Education, View, Program, Provost, Inclusion, Overalls, SIU, Student, Health, Disease, Health insurance, Pharmaceutical industry, Medicine, Meridian, Medicine, Southern Illinois University

CHICAGO, Aug. 11, 2022 /PRNewswire/ -- Meridian Health Plan of Illinois, Inc., a leading provider of government-sponsored managed care services in Illinois, and SIU Medicine, a publicly assisted medical school and clinical practice of Southern Illinois University in Carbondale, announced today the impact of the Provider Quality Improvement Initiative grant of $500,000 awarded by Meridian to the institution last September.

Key Points: 
  • The grant is the largest in SIU School of Medicine's Office of Equity, Diversity, and Inclusion's (OEDI) history.
  • Since the allocation of funds in September of 2021, SIU School of Medicine launched a new program called Health D.E.P.O.T.S.
  • Our grant directly supports SIU and its strategic Diversity, Equity, and Inclusion initiatives," said Sherry Husa, Meridian CEO and Plan President.
  • Meridian offers three managed care plans: the Meridian Medicaid Plan, the Meridian Medicare-Medicaid Plan, and the Meridian Managed Long-Term Services & Supports Plan.

Kheiron Medical Technologies Forms US Breast Medical Advisory Board; Appoints Three Leaders With Deep Track Record Advocating For Women's Health

Retrieved on: 
Wednesday, May 11, 2022
United Kingdom, School, Stanford University School of Medicine, Department, University, Mortality, MRI, Woman, Society, UC, Trailblazer, Emory University, Breast cancer, San Francisco, Social media, Patient, University of Missouri–Kansas City School of Medicine, Mammography, CEDM, Partnership, University of California, San Francisco, University of Texas Health Science Center Department of Radiology, Memorial Sloan Kettering Cancer Center, Cancer, Artificial intelligence, University of California, Davis, 2021 Essex County Council election, Machine learning, Leadership, Magnetic resonance imaging, Publication, Death, Disease, Science, Solution, CEO, Research, AI, Weill Cornell Medicine, Southern Illinois University School of Medicine, Intelligence, Medical device, Medical imaging, Radiology, Medicine, Kheiron

LONDON, May 11, 2022 /PRNewswire-PRWeb/ -- Kheiron Medical Technologies today announced the appointment of Dr. Wendy DeMartini, Dr. Elizabeth Morris, and Dr. Amy Patel to its US Breast Medical Advisory Board. These appointments reinforce Kheiron's focus on bringing its artificial intelligence solutions to the US market to help radiologists detect breast cancer earlier. Kheiron is committed to assembling an inclusive advisory board that shares its mission for creating equitable access to breast cancer screening, including among historically underserved populations. Through their work as leading authorities in breast cancer imaging, Dr. DeMartini, Dr. Morris, and Dr. Patel uniquely understand the challenges of delivering screening services and implementing AI solutions in settings ranging from underserved communities to world-class academic health centers. The US Breast Medical Advisory Board will work with Kheiron's consortium of research collaborators to serve as a crucial source of clinical partnership and expertise. Within North America, Kheiron works closely with UC San Francisco and Emory University, among others.

Key Points: 
  • Kheiron is committed to assembling an inclusive advisory board that shares its mission for creating equitable access to breast cancer screening, including among historically underserved populations.
  • The US Breast Medical Advisory Board will work with Kheiron's consortium of research collaborators to serve as a crucial source of clinical partnership and expertise.
  • Kheiron Medical Technologies has a true commitment to improving healthcare through artificial intelligence, with strong leadership, science and a global approach.
  • I am excited to participate on the US Breast Advisory Board to be a part of a revolution in breast imaging."

HPU Announces $32,000,000 Donor for New School of Dental Medicine

Retrieved on: 
Monday, May 9, 2022
High Point University, University of Puerto Rico School of Dental Medicine, Dentist, School, Student, GLOBE, Dentistry, Courage, Workman, HPU, Program, Family, Life skills, Leadership, Southern Illinois University School of Medicine, Chief Dental Officer (Canada), Heartland, University School, Education, Growth

Dr. Rick Workman is HPUs Dental Innovator in Residence and the founder of Heartland Dental, which supports more than 1,600 offices nationwide.

Key Points: 
  • Dr. Rick Workman is HPUs Dental Innovator in Residence and the founder of Heartland Dental, which supports more than 1,600 offices nationwide.
  • The new school will be named the Workman School of Dental Medicine.
  • More on the Workman School of Dental Medicine:
    HPU will establish the only private dental school in the state of North Carolina, which will be housed in a new 80,000-square-foot building on HPUs Innovation Corridor.
  • This is an incredible, transformational gift for the School of Dental Medicine, said Dr. Scott De Rossi, founding dean for the new school.

The Donerail Group and Board Nominee Terry Jimenez Issue Joint Statement Regarding the Firm’s Prior Acquisition Efforts and Financing Capabilities

Retrieved on: 
Tuesday, April 12, 2022
Banking, Professional Services, Finance, Former, Bangladesh Securities and Exchange Commission, Security (finance), NASDAQ, HFA, Common stock, UPON, Common, Director, News Media Alliance, Investment, Acquisition, Business, THE, Pressure, Partner, TPCO, Bank of America, Cayman Islands, Tribune Publishing, SCW, Harbert Management Corporation, Partnership, Nature, Board, Southern Illinois University School of Medicine, Judgement, LLC, Board of directors, Leadership, WEB, Bank, Principal, HMC, SEC, WHEN, Charitable organization, Time, Corporate services, Wilson, Turtle Beach Corporation, LP, NO, Financial services, Risk management, Auction, Video game console, Management, Company, Tribune, Nexstar Media Group

Since Donerails initial acquisition proposal in April 2021, we have tried to work collaboratively with the Company and its advisors at Bank of America to provide clarity regarding our acquisition financing capabilities.

Key Points: 
  • Since Donerails initial acquisition proposal in April 2021, we have tried to work collaboratively with the Company and its advisors at Bank of America to provide clarity regarding our acquisition financing capabilities.
  • Given Donerails acquisition proposal required significant co-investment equity capital, we understood the Board of Directors (the "Board") desire for information concerning our financing capabilities and co-investment capital raising experience.
  • Accordingly, the Boards representative informed Donerail that the Board no longer considered credibility of financing as a basis to object to our bid.
  • As the general partner of Donerail Group, Donerail Group GP may be deemed to beneficially own the 860,816 shares of Common Stock directly beneficially owned by Donerail Master Fund.

SYNTap Biomarker Test helps doctors distinguish Parkinson's Disease from Parkinsonism in early stages

Retrieved on: 
Wednesday, April 6, 2022
Linda, Substantia nigra, Chittagong Veterinary and Animal Sciences University, Southern Illinois University School of Medicine, Neurology, Diagnosis, Neurodegeneration, Oregon Health & Science University, Movement disorders, Dopamine, Body, Synuclein, School, Oregon Health Plan, PD, Basal ganglia, History, Alzheimer's disease, Neurological disorder, Progressive supranuclear palsy, Autopsy, Parkinson's disease, Time, Physician, Amprion, Movement, SAN, FDA, Patient, Disease, Medical imaging, Palladium, Pharmaceutical industry, Medical device, Parkinsonism

SAN FRANCISCO, April 6, 2022 /PRNewswire-PRWeb/ -- PD affects 10 million people globally. About one million Americans live with PD, and 60,000 new cases are added each year. Unfortunately, despite billions of spending in drug R&D over the past three decades, there is no cure for Parkinson's–yet.

Key Points: 
  • For the first time in history, Amprion's breakthrough SYNTap Biomarker Test can help doctors effectively distinguish Parkinson's Disease (PD) from Parkinsonism early.
  • Clinical diagnosis of PD is challenging, particularly at early stages when treatments are likely to be more effective.
  • For the first time in history, Amprion's breakthrough SYNTap Biomarker Test can help doctors effectively distinguish PD from Parkinsonism in early stages.
  • Our SYNTap Biomarker Test helps doctors diagnose Parkinson's, Lewy Body Dementia, and Alzheimer's with Lewy Bodies.

Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer

Retrieved on: 
Thursday, November 18, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Mayo Clinic, Principia, Head, University School, Endocrinology, Cancer, IL-6, Inflammation, Clinical professor, Therapy, All India Institute of Medical Sciences, New Delhi, Immunology, Cytokine, Clinical research, Development, India, NYU, B cell, Â, Antibody, Medicine, Internal medicine, Southern Illinois University School of Medicine, Fibrosis, National Institutes of Health Clinical Research Training Program, All India Institute of Speech and Hearing, Degenerative disease, Pharmaceutical industry

Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced the appointment of Puneet S. Arora, M.D.

Key Points: 
  • Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced the appointment of Puneet S. Arora, M.D.
  • As a highly regarded physician-scientist and drug developer, Puneets experience in inflammation and immunology will be instrumental to Lassen as we initiate our clinical program for LASN01, our first-in-class anti-IL-11R antibody, said Mark Barrett Chief Executive Officer of Lassen Therapeutics.
  • Dr. Arora managed clinical development for lead programs including early translational development and proof of concept through late development and regulatory submissions.
  • Lassen is pursuing compelling targets and novel mechanisms of action with the potential to result in important new therapeutics for patients with limited treatment options.